HER-2-mediated nano-delivery of molecular targeted drug potently suppresses orthotopic epithelial ovarian cancer and metastasis
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
HER-2-mediated nano-delivery of molecular targeted drug potently suppresses orthotopic epithelial ovarian cancer and metastasis
Authors
Keywords
-
Journal
INTERNATIONAL JOURNAL OF PHARMACEUTICS
Volume 625, Issue -, Pages 122126
Publisher
Elsevier BV
Online
2022-08-19
DOI
10.1016/j.ijpharm.2022.122126
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- α3 integrin-binding peptide-functionalized polymersomes loaded with volasertib for dually-targeted molecular therapy for ovarian cancer
- (2021) Zhe Wang et al. Acta Biomaterialia
- Daratumumab Immunopolymersome‐Enabled Safe and CD38‐Targeted Chemotherapy and Depletion of Multiple Myeloma
- (2021) Na Yu et al. ADVANCED MATERIALS
- Identification of PLK1 as a New Therapeutic Target in Mucinous Ovarian Carcinoma
- (2020) Roberta Affatato et al. Cancers
- Brain delivery of Plk1 inhibitor via chimaeric polypeptide polymersomes for safe and superb treatment of orthotopic glioblastoma
- (2020) Qianyi Fan et al. JOURNAL OF CONTROLLED RELEASE
- Actively targeted nanomedicines for precision cancer therapy: Concept, construction, challenges and clinical translation
- (2020) Wenxing Gu et al. JOURNAL OF CONTROLLED RELEASE
- Epithelial ovarian cancer
- (2019) Stephanie Lheureux et al. LANCET
- Cisplatin-loaded PLGA nanoparticles for HER2 targeted ovarian cancer therapy
- (2019) Rossina Domínguez-Ríos et al. COLLOIDS AND SURFACES B-BIOINTERFACES
- Randomized Trial of Intravenous Versus Intraperitoneal Chemotherapy Plus Bevacizumab in Advanced Ovarian Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study
- (2019) Joan L. Walker et al. JOURNAL OF CLINICAL ONCOLOGY
- HER2-Specific Reduction-Sensitive Immunopolymersomes with High Loading of Epirubicin for Targeted Treatment of Ovarian Tumor
- (2019) Lin Ding et al. BIOMACROMOLECULES
- HER2-targeted therapies — a role beyond breast cancer
- (2019) Do-Youn Oh et al. Nature Reviews Clinical Oncology
- A view on drug resistance in cancer
- (2019) Neil Vasan et al. NATURE
- Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer
- (2019) Isabelle Ray-Coquard et al. NEW ENGLAND JOURNAL OF MEDICINE
- Intraperitoneal Route of Drug Administration: Should it Be Used in Experimental Animal Studies?
- (2019) Abdullah Al Shoyaib et al. PHARMACEUTICAL RESEARCH
- Ovarian cancer statistics, 2018
- (2018) Lindsey A. Torre et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Impact of iASPP on chemoresistance through PLK1 and autophagy in ovarian clear cell carcinoma
- (2018) Ka-Kui Chan et al. INTERNATIONAL JOURNAL OF CANCER
- Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
- (2018) Kathleen Moore et al. NEW ENGLAND JOURNAL OF MEDICINE
- Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
- (2017) Eric Pujade-Lauraine et al. LANCET ONCOLOGY
- Playing polo during mitosis: PLK1 takes the lead
- (2017) G Combes et al. ONCOGENE
- PARP inhibitors: Synthetic lethality in the clinic
- (2017) Christopher J. Lord et al. SCIENCE
- PLK1, A Potential Target for Cancer Therapy
- (2017) Zhixian Liu et al. Translational Oncology
- Simultaneous targeting of CD44 and EpCAM with a bispecific aptamer effectively inhibits intraperitoneal ovarian cancer growth
- (2017) Jingying Zheng et al. Theranostics
- Engineered fusion protein-loaded gold nanocarriers for targeted co-delivery of doxorubicin and erbB2-siRNA in human epidermal growth factor receptor-2+ ovarian cancer
- (2017) Rajesh Kotcherlakota et al. Journal of Materials Chemistry B
- Volasertib Versus Chemotherapy in Platinum-Resistant or -Refractory Ovarian Cancer: A Randomized Phase II Groupe des Investigateurs Nationaux pour l'Etude des Cancers de l'Ovaire Study
- (2016) Eric Pujade-Lauraine et al. JOURNAL OF CLINICAL ONCOLOGY
- Spotlight on Volasertib: Preclinical and Clinical Evaluation of a Promising Plk1 Inhibitor
- (2016) J. Van den Bossche et al. MEDICINAL RESEARCH REVIEWS
- Plk1 Inhibitors in Cancer Therapy: From Laboratory to Clinics
- (2016) Rosie Elizabeth Ann Gutteridge et al. MOLECULAR CANCER THERAPEUTICS
- Delivering widespread BRCA testing and PARP inhibition to patients with ovarian cancer
- (2016) Angela George et al. Nature Reviews Clinical Oncology
- Can advanced-stage ovarian cancer be cured?
- (2016) Steven Narod Nature Reviews Clinical Oncology
- Control of polymeric nanoparticle size to improve therapeutic delivery
- (2015) John W. Hickey et al. JOURNAL OF CONTROLLED RELEASE
- Investigating the Impact of Nanoparticle Size on Active and Passive Tumor Targeting Efficiency
- (2014) Edward A. Sykes et al. ACS Nano
- Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy
- (2014) H. Dohner et al. BLOOD
- Discovery and development of the Polo-like kinase inhibitor volasertib in cancer therapy
- (2014) B T Gjertsen et al. LEUKEMIA
- A phase I, dose-escalation study of the novel Polo-like kinase inhibitor volasertib (BI 6727) in patients with advanced solid tumours
- (2011) Patrick Schöffski et al. EUROPEAN JOURNAL OF CANCER
- BI 6727, A Polo-like Kinase Inhibitor with Improved Pharmacokinetic Profile and Broad Antitumor Activity
- (2009) D. Rudolph et al. CLINICAL CANCER RESEARCH
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started